	Srodki Pieniężne I Ekwiwalent		Data
AbbVie	USD 5.23B	400M	2025-12
Amgen	USD 9.13B	316M	2025-12
Anika Therapeutics	USD 57.99M	4.82M	2025-09
Arrowhead Research	USD 201.64M	112.94M	2025-12
AstraZeneca	USD 8.14B	1.08B	2025-09
BioCryst Pharmaceuticals	USD 84.08M	3.95M	2025-09
Biogen	USD 3.01B	854.3M	2025-12
Bristol-Myers Squibb	USD 10.21B	5.52B	2025-12
Enanta Pharmaceuticals	USD 37.44M	5.14M	2025-12
Gilead Sciences	USD 7.33B	2.19B	2025-09
GlaxoSmithKline	GBP 3.3B	303M	2025-09
Halozyme Therapeutics	USD 133.82M	285.84M	2025-12
Heron Therapeutics	USD 43.07M	26.55M	2025-09
Immunic	USD 35.13M	20.18M	2025-09
Incyte	USD 3.58B	650.78M	2025-12
Insmed	USD 510.44M	175.68M	2025-12
Ionis Pharmaceuticals	USD 2.68B	437M	2025-12
J&J	USD 19.71B	1.48B	2025-12
Karyopharm Therapeutics	USD 37.67M	1.05M	2025-09
Ligand Pharmaceuticals	USD 174.93M	489.59M	2025-12
Merck	USD 18.17B	10.16B	2025-09
Neurocrine Biosciences	USD 713M	372.8M	2025-12
Novartis	USD 9.56B	2.9B	2025-09
Novavax	USD 268.02M	14.28M	2025-09
Pfizer	USD 1.34B	295M	2025-09
PTC Therapeutics	USD 984.65M	312.03M	2025-12
Roche Holding	CHF 7.55B	579M	2025-06
Sarepta Therapeutics	USD 801.28M	188.2M	2025-12
Vertex Pharmaceuticals	USD 6.61B	321.1M	2025-12

Enanta Pharmaceuticals Srodki Pieniężne I Ekwiwalent - Aktualne wartości, dane historyczne, prognozy, statystyki, wykresy i kalendarz ekonomiczny - Mar 2026.